Ignite Creation Date:
2024-05-05 @ 4:43 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00291798
Status:
COMPLETED
Last Update Posted:
2006-09-19
First Post:
2006-02-14
Brief Title:
Neoadjuvant Endocrinotherapy of Breast Cancer Mamma Carcinoma With Exemestane
Sponsor:
Austrian Breast Colorectal Cancer Study Group
Organization:
Austrian Breast Colorectal Cancer Study Group
Study Overview
Official Title:
Neoadjuvant Endocrinotherapy of Mamma Carcinoma With Exemestane
Status:
COMPLETED
Status Verified Date:
2006-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of the present clinical investigation is to determine whether hormonal therapy given preoperatively is able to reduce tumor size to an extent that facilitates breast-conserving procedures
Detailed Description:
This open prospective multicenter Phase II pilot trial investigates the efficacy of exemestane 25 mg once daily over 4 months in postmenopausal women with primary breast cancer measured in terms of clinical response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None